Corcept officer plans $8.3M Rule 144 stock sale

Rhea-AI Filing Summary

CORCEPT THERAPEUTICS INC (CORT) has a notice of proposed sale under Rule 144 for up to 75,295 shares of common stock for the account of officer Roberto Wandenkolk Vieira, to be sold through Stifel Nicolaus & Company Inc. The shares include 74,999 acquired through a stock option exercise on February 1, 2024 and 296 acquired through an ESPP purchase on September 1, 2026. The notice cites an aggregate market value of $8,339,418 and 108,098,397 shares of common stock outstanding, with an approximate sale date of September 2, 2026.

Key Figures

Shares to be sold: 75,295 shares Aggregate market value: $8,339,418 Shares outstanding: 108,098,397 shares +3 more

6 metrics

Shares to be sold 75,295 shares Maximum number of CORCEPT common shares covered by the Rule 144 notice

Aggregate market value $8,339,418 Aggregate market value of the 75,295 shares covered by the notice

Shares outstanding 108,098,397 shares CORCEPT common shares outstanding referenced in the Rule 144 filing

Option shares acquired 74,999 shares Shares acquired via stock option exercise on February 1, 2024 from the issuer

ESPP shares acquired 296 shares Shares acquired via ESPP purchase on September 1, 2026 from the issuer

Approximate sale date September 2, 2026 Approximate date of sale for the shares covered by the notice

Key Terms

Rule 144, Stock Option Exercise, ESPP

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Stock Option Exercise financial

"Common Stock | 02/01/2024 | Stock Option Exercise | Issuer"

A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.

ESPP financial

"Common Stock | 09/01/2026 | ESPP | Issuer"

An Employee Stock Purchase Plan (ESPP) is a company program that lets employees buy the company’s shares at a reduced price, usually by setting aside a small portion of their pay over time. It matters to investors because it encourages employees to own part of the business—like giving staff a discounted membership— which can boost commitment and performance, while also potentially increasing the number of shares available and affecting shareholder value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is being disclosed for CORT in this Form 144 filing?

The filing discloses a proposed Rule 144 sale of up to 75,295 shares of CORCEPT THERAPEUTICS INC common stock for the account of officer Roberto Wandenkolk Vieira, to be executed through Stifel Nicolaus & Company Inc around September 2, 2026.

How many CORT shares is the insider planning to sell and what is their value?

The notice covers up to 75,295 shares of CORCEPT THERAPEUTICS INC common stock, with an indicated aggregate market value of $8,339,418 as stated in the filing.

How were the CORT shares in this Form 144 acquired?

Of the shares covered, 74,999 were acquired through a stock option exercise dated February 1, 2024 and 296 shares were acquired through an ESPP purchase on September 1, 2026, both from the issuer.

What is the reported number of CORT shares outstanding in this notice?

The notice lists 108,098,397 shares of CORCEPT THERAPEUTICS INC common stock outstanding, used as a reference figure in connection with the proposed Rule 144 sale.

Who is the broker for the planned Rule 144 sale of CORT shares?

The proposed sale of CORCEPT THERAPEUTICS INC common stock is to be executed through Stifel Nicolaus & Company Inc, which is identified as the broker in the filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/02/2026 - 04:09 PM EDT Accepted by SEC EDGAR 09/02/2026 - 04:08 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002150104
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	CORCEPT THERAPEUTICS INC
SEC File Number	000-50679
Address of Issuer	101 REDWOOD SHORES PARKWAY REDWOOD CITY CALIFORNIA 94065
Phone	650.688.8803
Name of Person for Whose Account the Securities are To Be Sold	Vieira Roberto Wandenkolk
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Stifel Nicolaus & Company Inc 501 N Broadway St. Louis MO 63102	75295	8339418.00	108098397	09/02/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	02/01/2024	Stock Option Exercise	Issuer			74999	09/02/2026	Cash
Common Stock	09/01/2026	ESPP	Issuer			296	09/01/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	09/02/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	06/17/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ James Weimer, as a duly authorized representative of STIFEL, as attorney-in-fact for Roberto Vieira
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)